Table 1.
Age-related macular degeneration patients treated with Ironing PDT
| Case no | Age (years) | AMD type | CNV lesion | The reason for choosing PDT | BCVA before Ironing PDT | BCVA 36 months after Ironing PDT | Additional treatments in 36 months follow-up | Macular findings 36 months after Ironing PDT |
|---|---|---|---|---|---|---|---|---|
| 1 | 75 | PCV | Peripapillary | Cerebrovascular infarction | 0.15 | 0.1 | Ironing PDT ×3 | Scarring |
| 2 | 83 | PCV | Peripapillary | Cerebrovascular infarction | 0.08 | 0.05 | None | Scarring |
| 3 | 78 | PCV | Large | Cerebrovascular infarction | 0.04 | 0.05 | PPV for vitreous hemorrhage | Scarring |
| 4 | 75 | tAMD | Peripapillary | Tachyphylaxis to IVB | 0.05 | 0.1 | None | Scarring |
| 5 | 57 | tAMD | Large | Refuse IVR | 0.08 | 0.08 | None | Scarring |
| 6 | 77 | tAMD | Large | Cardiovascular disease | 0.2 | 0.08 | None | Exudative |
| 7 | 72 | tAMD | Large | Nonresponder to IVR | 0.6 | 0.15 | Ironing PDT with IVR ×2 | Scarring |
| 8 | 74 | PCV | Peripapillary | Tachyphylaxis to IVR | 0.1 | 0.1 | Ironing PDT with IVR | Exudative |
Notes: There was no significant difference between the mean logMAR BCVA before treatment and the mean logMAR BCVA after treatment (P=0.809, paired t-test). The logMAR BCVA improved in one eye (12.5%), was maintained in five eyes (62.5%), and deteriorated in two eyes (25.0%).
Abbreviations: BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; IVB, intravitreous bevacizumab; IVR, intravitreous ranibizumab; logMAR, logarithm of the minimum angle of resolution; PCV, polypoidal choroidal vasculopathy; PDT, photodynamic therapy; PPV, pars plana vitrectomy; tAMD, typical age-related macular degeneration.